Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4 Registration of securities issued in business combination transactions
- 10.34 EX-10.34
- 10.35 EX-10.35
- 10.36 EX-10.36
- 10.37 EX-10.37
- 10.38 EX-10.38
- 10.39 EX-10.39
- 10.40 EX-10.40
- 10.41 EX-10.41
- 10.42 EX-10.42
- 10.43 EX-10.43
- 10.44 EX-10.44
- 10.45 EX-10.45
- 10.46 EX-10.46
- 10.47 EX-10.47
- 10.48 EX-10.48
- 21.1 EX-21.1
- 23.1 EX-23.1
- 23.5 EX-23.5
- 99.5 EX-99.5
- 99.6 EX-99.6
- 99.7 EX-99.7
- 99.8 EX-99.8
- 99.9 EX-99.9
- Download Excel data file
- View Excel data file
NRBO similar filings
- 4 Nov 19 Registration of securities issued in business combination transactions (amended)
- 30 Oct 19 Registration of securities issued in business combination transactions (amended)
- 10 Oct 19 Registration of securities issued in business combination transactions (amended)
- 3 Sep 19 Registration of securities issued in business combination transactions
Filing view
External links
Consent of Independent Registered Public Accounting Firm
NeuroBo Pharmaceuticals, Inc.
Boston, Massachusetts
We hereby consent to the use in the Prospectus constituting a part of this Registration Statement on Form S-4 of our report dated August 30, 2019, relating to the consolidated financial statements of NeuroBo Pharmaceuticals, Inc. (the “Company”), which is contained in that Prospectus. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
We also consent to the reference to us under the caption “Experts” in the Prospectus.
/s/ BDO USA, LLP |
|
Boston, Massachusetts |
|
|
|
August 30, 2019 |
|